22UA:FRA
BioNTech SE - ADR
80,25 €
arrow_upward
+0,82%(+0,65) 1D
16-окт., 12:42:30 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
80,15 €
High
81,25 €
Low
80,15 €
Mkt. cap
22,66 млд
Avg. vol.
1,43 миң
Volume
203,00
52-wk high
105,50 €
52-wk low
68,00 €
No. of employees
8 миң
Open
80,15 €
High
81,25 €
Low
80,15 €
Mkt. cap
22,66 млд
Avg. vol.
1,43 миң
Volume
203,00
52-wk high
105,50 €
52-wk low
68,00 €
No. of employees
8 миң
News stories
From web sources and news partners
ad-hoc-news.de
·
18 саат мурун
Canaccord cuts target for BioNTech stock to USD 132.00
Pluang
·
1 күн мурун
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
2 күн мурун
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
TipRanks
·
2 күн мурун
BioNTech Presses Ahead With BNT113 Cancer Trial After Initial Endpoint Miss
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR